



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

1/24/97
TOWNSEND and TOWNSEND and CREW LLP

By Rain M. Williams

0500
1804
2/28/97
#4 MB
2/21/97
PATENT
Attorney Docket No. 014643-009020US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)

NILS LONBERG et al.)

Application No.: 08/728,463)

Filed: 10 October, 1996)

For: TRANSGENIC NON-HUMAN
ANIMALS FOR PRODUCING
HETEROLOGOUS ANTIBODIES)

97 FEB 19 PM 4:43
GROUP 30
RECEIVED
Examiner: UNASSIGNED

Art Unit: UNASSIGNED

INFORMATION DISCLOSURE
STATEMENT UNDER

37 CFR \$1.97 and \$1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The disclosures cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of some of the disclosures (references A1-C96) are not being provided pursuant to 37 C.F.R. 1.98(d), as those disclosures have been previously cited by or submitted to the Patent Office in prior applications Serial Nos. 07/810,279, 07/853,408, 08/161,739, 08/165,699, 08/096,762, 08/352,322, and 08/209,741, to which the above identified application claims priority.


This information disclosure statement is being filed before the mailing date of the first office action on the merits.

Niels LONGBERG et al.
Application No.: 08/728,463
Page 2

PATENT

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the disclosures be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Respectfully submitted,



Randolph T. Apple
Reg. No. 36,429

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
(415) 576-0200
Fax (415) 576-0300
RTA:dmv

h:\home\RTA\WORK\GENPHARM\90-2\IDS